All In Biotech

Drug Trial Radar · NCT06387628

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

Jul 10, 2024

Primary completion

Apr 1, 2026

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.

Conditions

  • TNBC - Triple-Negative Breast Cancer

Interventions

  • LM-108Drug

    LM-108, 10mg/kg, d1, q6w

  • ToripalimabDrug

    Toripalimab, 240 mg, d1, q3w

  • EribulinDrug

    Eribulin 1.4 mg/m2, d1, 8 , q3w

  • Nab paclitaxelDrug

    Nab paclitaxel 125 mg/m2, d1, 8 , q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.